Latest:
Narsoplimab Trial Results
The panel of transplant experts discuss the results of the phase 2 trial of narsoplimab and the pending FDA approval of this agent for treatment of transplant-associated of thrombotic microangiopathy.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Christophe Mariette, MD, PhD
Latest:
Dr. Mariette on Takeaways from a Study of Esophageal and Gastric Cancer Surgery
Christophe Mariette, MD, PhD, surgical oncologist, professor of Surgery, University Hospital of Lille, discusses the main takeaways from a study investigating postoperative mortality after patients undergo surgery for esophageal and gastric cancer.
Christopher Crane, MD
Latest:
Dr. Crane on the Use of Proton Therapy and the MR-Linear Accelerator in GI Malignancies
Christopher Crane, MD, vice chair, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, discusses the emergence and success of new technologies in the treatment of patients with gastrointestinal (GI) malignancies.
Christopher Dittus, DO, MPH
Latest:
How to Survive With Limited Finances (and a Family) as a Hematology-Oncology Fellow
If you are anything like me, despite working incredibly hard, not getting paid adequately for many years, and accumulating an incredible amount of debt, you could not imagine any other career.
Christopher E. Barbieri, MD, PhD
Latest:
Dr. Barbieri on SPOP Mutations in Prostate Cancer
Christopher E. Barbieri, MD, PhD, surgeon, researcher in prostate cancer genomics, Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine and New-York Presbyterian, discusses the implications of SPOP mutations in patients with prostate cancer.
Christopher E. Dandoy, MD, MSc
Latest:
Dr. Dandoy on Overcoming Challenges with TA-TMA
Christopher E. Dandoy, MD, MSc, shares advice for how to overcome the challenges in managing transplanted-associated thrombotic microangiopathy. The primary challenges are diagnosing and identifying TA-TMA in patients.
Christopher H. Crane, MD
Latest:
Radiation Dose Escalation to the Tumor-Arterial Interface of Locally Advanced and Borderline Resectable Pancreatic Cancer
An integrated boost with conventional fractionation to the tumor-arterial interface is unlikely to lead to downstaging in borderline resectable and locally advanced pancreatic cancer.
Christopher Lieu, MD
Latest:
AE Management of Cabozantinib
Panelists discuss how managing cabozantinib’s adverse effects requires proactive patient counseling about expected dose reductions, aggressive supportive care for manageable toxicities like hypertension and diarrhea, frequent early monitoring, and recognition that the median effective dose (40 mg) is lower than the starting dose (60 mg).
Christopher P. Evans, MD
Latest:
Dr. Evans Discusses the Subgroup Analysis Results of the PREVAIL Study
Christopher P. Evans, MD, professor, chairman, Department of Urology, University of California at Davis School of Medicine, UC Davis Comprehensive Cancer Center, discusses the results of an analysis of patients with and without visceral disease defined as liver and/or lung metastases who participated in the PREVAIL study.